HB0767 is a broad health-regulation and pharmacy-policy bill that makes multiple changes across Illinois law, primarily in the Civil Administrative Code, the Department of Public Health Act, the Illinois Insurance Code, and the Pharmacy Practice Act. It revises the role and composition of the Immunization Advisory Committee, expands the Department of Public Health’s authority to issue and publish communicable disease and immunization guidance, and requires health insurance coverage for certain vaccines and preventive services without cost-sharing in specified circumstances. The bill also updates pharmacist practice rules, including expanded authority related to vaccinations, point-of-care testing, and certain treatments, while tying those services to training, reporting, and supervision requirements.
A major portion of the bill focuses on pharmacy benefit managers (PBMs), drug pricing, and prescription drug affordability. It imposes new reporting requirements on PBMs, creates or revises registration and fee provisions, and establishes a Prescription Drug Affordability Fund and related transfer mechanisms. The bill also creates a DCEO Projects Fund-supported pharmacy support program, funded in part by amounts collected under the PBM provisions, to provide grants to support pharmacies. In addition, it restricts spread pricing, limits steering to affiliated pharmacies, regulates maximum allowable cost lists and appeals, requires rebate pass-through and disclosure, and bars discriminatory treatment of 340B entities and pharmacies.
The bill’s impact on state law is substantial because it adds new statutory sections and amends existing ones to expand state oversight of public health guidance, pharmacy practice, insurance coverage, and PBM conduct. It affects insurers, health benefit plans, PBMs, pharmacies, 340B entities, Medicaid-related arrangements, and public health officials. It also includes applicability provisions that reach many health benefit plans and contracts beginning in 2025 or 2026, while carving out certain federal plans and other exempt arrangements.
Overall sentiment appears generally supportive of stronger public health authority, broader vaccine and preventive-care coverage, and tighter regulation of PBM and drug-pricing practices. Because no committee transcripts or recorded votes were provided, there is no direct evidence of debate or opposition in the supplied materials. However, the structure of the bill suggests likely support from pharmacy, public health, and consumer-affordability advocates, alongside potential concern from insurers, PBMs, and other drug-benefit administrators over compliance costs, reporting burdens, and restrictions on pricing and network design.
Notable points of contention likely center on the PBM provisions, especially the bans on spread pricing and steering, the disclosure of rebate and contract information, the limits on reimbursement practices, and the requirement to pass through rebates and fees. Another likely area of debate is the expansion of state-guided immunization policy and insurance coverage mandates, including the role of the Immunization Advisory Committee and the requirement that insurers cover certain vaccines and related services without cost-sharing. The bill also contains detailed carve-outs and delayed effective dates, indicating an effort to balance new regulatory requirements with existing federal preemption issues and operational transition concerns.
HB0767 amends multiple Illinois statutes to expand public health governance, broaden pharmacist scope-of-practice provisions, mandate insurance coverage for specified vaccines and preventive services, and impose extensive regulation on pharmacy benefit managers and related drug-pricing practices. It creates new reporting, registration, fee, audit, and enforcement requirements for PBMs; establishes new funds and grant mechanisms for pharmacy support; and adds protections for 340B entities, pharmacies, and covered individuals. The bill also affects insurers, managed care plans, Medicaid-related arrangements, and self-funded governmental plans through detailed applicability and exemption language.
The overall sentiment in the available materials appears favorable toward the bill’s goals of improving access to vaccines, strengthening public health guidance, supporting pharmacies, and increasing transparency in prescription drug pricing. No committee transcript or vote record was provided, so there is no direct evidence of formal opposition or support in the supplied context. Based on the bill’s content, support would likely come from public health and pharmacy stakeholders, while insurers and PBMs would be more likely to object to the regulatory and financial burdens.
The most likely points of contention are the bill’s restrictions on PBM business practices, including spread pricing, steering, reimbursement methodologies, rebate retention, and network discrimination, as well as the extensive reporting and audit requirements. Insurers and PBMs may also object to the bill’s coverage mandates for vaccines and preventive services, the expansion of state authority over immunization guidance, and the treatment of 340B entities. Another possible dispute is the bill’s reach into self-funded and governmental plans, though the text includes several federal-law-based carve-outs and delayed effective dates to address preemption and implementation concerns.